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Abstract
 
Diabetes is a significant and growing concern, with over 246 million people around the world living with the disease and
another 308 million with impaired glucose tolerance. Depending on the resources of different nations, intervention has
generally focused on optimizing overall glycaemic control as assessed by glycated haemoglobin (HbA
 
1c
 
) and fasting plasma
glucose (FPG) values. Nevertheless, increasing evidence supports the importance of controlling all three members of the
glucose triad, namely HbA
 
1c
 
, FPG and postmeal glucose (PMG) in order to improve outcome in diabetes. As part of its
global mission to promote diabetes care and prevention and to find a cure, the International Diabetes Federation (IDF)
recently developed a guideline that reviews evidence to date on PMG and the development of diabetic complications.
Based on an extensive database search of the literature, and guided by a Steering and Development Committee including
experts from around the world, the 
 
IDF Guideline for Management of Postmeal Glucose
 
 offers recommendations for
appropriate clinical management of PMG. These recommendations are intended to help clinicians and organizations in
developing strategies for effective management of PMG in individuals with Type 1 and Type 2 diabetes. The following
review highlights the recommendations of the guideline, the supporting evidence provided and the major conclusions
drawn. The full guideline is available for download at www.idf.org.
Diabet. Med. 25, 1151–1156 (2008)
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Introduction
 
Diabetes has no geographical boundaries and the disease, once
ascribed to more affluent countries, is now known to profoundly
affect developing nations [1]. More than 246 million people
around the world are now living with diabetes and 308 million
people are estimated to have impaired glucose tolerance (IGT)
[1]. These alarming figures translate to an estimated 3.8 million
people succumbing to the disease in the past year [1].
As a global issue, diabetes outcome is closely tied to the
management strategies and resources available in the various
regions of the world. However, even within the limitations of
healthcare resources in certain nations, there is a need to
optimize diabetes management to minimize related morbidity
and mortality. Among the many methods recognized for
improving outcome in diabetes, such as lifestyle modification
and control of related risk factors, the importance of tailoring
therapies to achieve specific glycaemic targets is increasingly
apparent. Traditionally, intervention has largely focused on
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optimizing overall glycaemic control as assessed by glycated
haemoglobin (HbA
 
1c
 
) and fasting plasma glucose (FPG) values
[2]. However, studies have highlighted the importance of
targeting postmeal hyperglycaemia and demonstrate a strong
relationship between elevated postmeal glucose (PMG) and
the risk of complications [3–7].
As part of its global mission to promote diabetes care and pre-
vention and to find a cure, the International Diabetes Federation
(IDF) has developed a guideline that reviews the relationship
between PMG and the development of diabetes complications,
as well as recommendations for the appropriate management
of PMG. Below is an overview of the guideline’s major conclusions
and recommendations for management of postmeal glycaemia.
 
Origin of guideline
 
The postmeal guideline was developed under the direction of
the IDF, through consultation of a Steering Committee (four
members) and Development Committee (14 members). These
committees were composed of individuals from around the
world experienced at guideline development and healthcare
delivery and living with diabetes [8]. A series of four
key questions served as the basis for an extensive, systematic
search of the literature published over the past 20  years.
Question 1: Is postprandial hyperglycaemia harmful? Question 2:
Is treatment of postmeal hyperglycaemia beneficial? Ques-
tion 3: Which therapies are effective in controlling postmeal
plasma glucose? Question 4: What are the targets for postmeal
glycaemic control and how should they be assessed? Relevant
reports were obtained through a computerized search of the
literature using PubMed and other search engines; scanning
of incoming journals in the medical library and review of
references in pertinent review articles, major textbooks and
syllabi from national and international meetings on the
subjects of diabetes, using relevant title and text words (e.g. post-
prandial, postmeal, hyperglycaemia, mealtime, self-monitoring,
oxidative stress, inflammation) as search criteria. The committee
reviewed over 1600 studies and numerous key reports before
making recommendations based on the strength of the
evidence. The draft guideline, which extended to management
of both Type 1 and Type 2 diabetes, was distributed for wider
review by IDF member associations, global and regional IDF
elected representatives, interested professionals, industry and
others on IDF contact lists.
 
Rationale for postmeal glucose control
 
In people with normal glucose tolerance, plasma glucose
generally rises no higher than 7.8 mmol/l (140 mg/dl) (which
reflects the World Health Organization definition) [9]. For this
guideline, postmeal hyperglycemia is defined as a plasma glucose
level > 7.8 mmol/l (140 mg/dl) 2 h after the ingestion of food.
Development of postmeal hyperglycaemia coincides with a
loss of first-phase insulin secretion, a decrease in insulin
sensitivity and an inability to adequately suppress hepatic
glucose production [10–12]. As frank diabetes develops [11],
PMG excursions continue to worsen [13]. The contribution of
postmeal plasma glucose to HbA
 
1c
 
 is proportionally greatest
with HbA
 
1c
 
 values of 6.5%, while nocturnal FPG is at a
near-normal level. As HbA
 
1c
 
 rises above 8%, the relative
contribution of postmeal hyperglycaemia to overall glycaemic
control diminishes, while the contribution of FPG predominates
[13]. These results explain previous findings that, while the
contribution of postmeal plasma glucose to overall glycaemia
is ~70% at HbA
 
1c
 
 values < 7.3%, the postmeal contribution is
~40% with HbA
 
1c
 
 values above 9.3% [14]. Such findings form
the basis for a glucose triad model of diabetes management, in
which all three glycaemic parameters of HbA
 
1c
 
, PMG and
FPG interrelate, and are essential targets for intervention in
attempts to optimize overall glycaemic control (Fig. 1).
Postmeal or post-challenge hyperglycaemia is common in
the diabetes population and is commonly found even in
individuals considered to have adequate overall metabolic or
glycaemic control. A cross-sectional study in the USA involving
218 individuals with Type 2 diabetes identified post-challenge
glucose values 
 
≥
 
 11.1 mmol/l (200 mg/dl) in nearly 74% of
individuals overall and in 39% of those with HbA
 
1c
 
 values
< 7.0% [15]. Individuals with Type 1 diabetes on ‘intensive’
insulin therapy are also typically subject to these glycaemic
excursions, with 72-h continuous monitoring recording
postmeal elevations above 7.8 mmol/l (140 mg/dl) in 77% of
this patient population [16].
The closer the achieved HbA
 
1c
 
 is to the normal range, the
lower the risk of complications [17,18]. Given that PMG is
a major contribution to overall glycaemia across a range of
HbA
 
1c
 
 values [14], targeting postmeal hyperglycaemia may
help reduce risk of complications. The evidence and recommen-
dations for the management of PMG are reviewed.
 
Question 1: Is postprandial hyperglycaemia harmful?
 
Epidemiological studies have identified postmeal and post-
challenge hyperglycaemia as independent risk factors for
FIGURE 1 Glycated haemoglobin (HbA1c), postmeal glucose (PMG) and 
fasting plasma glucose (FPG) interrelate and are essential targets for 
intervention in attempts to optimize overall glycaemic control. 
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macrovascular disease in individuals with IGT and Type 2
diabetes [4,7,19–22]. Findings from two large-scale studies,
the European ‘DECODE’ and the Asian ‘DECODA’ study,
demonstrated 2-h plasma glucose to be a strong predictor of
cardiovascular disease and all-cause mortality [20,21] and a
better indicator than fasting glucose [21]. In addition, a
meta-analysis of 38 prospective studies confirmed that, while
cardiovascular risk increases linearly within a wide range
of 2-h plasma glucose values, a threshold effect is detected for
FPG values up to ~5.6 mmol/l (100 mg/dl) [4]. Postmeal hyper-
glycaemia more reliably predicted incidence of cardiovascular
events in individuals with Type 2 diabetes than elevations in
FPG, with cardiovascular risk greater in women than men
when comparing the top vs. bottom tertiles of post-lunch
plasma glucose values [19].
Along with population studies demonstrating an association
between postmeal hyperglycaemia and macrovascular risk,
surrogate markers of cardiovascular disease also appear to
depend on PMG elevations. Even mild-to-moderate postmeal
hyperglycaemia in individuals without diabetes was demon-
strated to be an independent risk factor for development of
carotid intima-media thickness (CIMT), a marker of
atherosclerosis [7]. In addition, a causal association was found
between postmeal hyperglycaemia and oxidative stress, inflam-
mation and endothelial dysfunction [23,24] and adhesion
molecules [25]. Significant reductions in myocardial blood
flow and blood volume are observed following ingestion
of a mixed meal in individuals with Type 2 diabetes, while
such myocardial perfusion deficits are not found during the
postmeal state in individuals without diabetes [26].
A number of other diabetes-related conditions are also
associated with postmeal and post-challenge hyperglycemia,
including independent correlation with diabetic retinopathy
and neuropathy, as well as an association with diabetic
nephropathy [3], increased cancer risk [27] and cognitive
dysfunction in elderly individuals with Type 2 diabetes [28].
 
Recommendation
 
• Postmeal hyperglycaemia is harmful and should be addressed.
 
Question 2: Is treatment of postmeal hyperglycaemia 
beneficial?
 
Although randomized controlled trials have not yet
established whether controlling postmeal glycaemia will in
itself reduce macrovascular or microvascular risk, evidence
suggests that therapies ‘preferentially’ targeting postmeal
hyperglycaemia appear to be beneficial [5,29,30]. Treatment
with acarbose, an 
 
α
 
-glucosidase inhibitor that delays carbo-
hydrate absorption following meals, significantly reduced postmeal
hyperglycaemia, along with risk of myocardial infarction and
other cardiovascular events in individuals with Type 2 diabetes
[5] and IGT [30]. A positive effect is also observed on CIMT
in individuals with Type 2 diabetes with the use of repaglinide,
a rapid-acting insulin secretagogue that preferentially targets
PMG; after a 1-year study period, regression of CIMT (i.e.
decrease in CIMT of > 0.02 mm) was observed in 52% of
individuals receiving repaglinide, compared with only 18% of
those treated with glibenclamide (glyburide) [29]. Similar
findings are observed in individuals with IGT, demonstrating
that acarbose therapy reduces CIMT progression compared
with placebo control [31]. Rapid-acting insulin analogues also
appear to have a positive effect on surrogate markers of
cardiovascular disease, including nitrotyrosine, endothelial
function and methylglyoxal (MG) and 3-deoxyglucosone (3-DG)
[32–34], with acarbose treatment also showing some similar
effects on these markers [35].
Along with evidence for a reduction in macrovascular risk
with treatments that preferentially target PMG in individuals
with Type 2 diabetes [5,29,30], findings from recent interven-
tional studies demonstrate that targeting postmeal hypergly-
caemia helps optimize HbA
 
1c
 
 [6,36]. Individuals with Type 2
diabetes achieving a target HbA
 
1c
 
 
 
≤
 
 7.0% had significantly
lower PMG values after the end of a 3-month intensified
diabetes management programme compared with those who
did not [6]. Fasting levels were not significantly different
between the two groups, suggesting that, although control of
FPG alone was necessary, it was not sufficient for achieving
the HbA
 
1c
 
 target. In addition, severe hypoglycaemia was not
associated with targeting postmeal hyperglycaemia.
 
Recommendation
 
• Implement treatment strategies to lower postmeal plasma
glucose in people with postmeal hyperglycaemia.
 
Question 3: Which therapies are effective in controlling 
postmeal plasma glucose?
 
Guidelines from various professional diabetes organizations
continue to encourage physical activity, nutritional intervention
and weight control as essential components of a comprehensive
programme for diabetes management [37–39]. Nevertheless,
the precise composition of the ‘optimal’ diet is still debated,
although reducing glycaemic load (GL) has emerged as a
favourable option [40,41]. Glycaemic load is an estimate of
the glycaemic effects of a diet, accounting for both the type of
carbohydrate consumed [i.e. according to the glycaemic index
(GI)] and the amount [40]. With glycaemic load and glycaemic
index reliably predicting the glycaemic response following a
mixed meal [40,41], nutritional planning that incorporates
these measures may not only reduce PMG excursions but is
also found to modestly lower HbA
 
1c
 
 [42] and possibly reduce
cardiovascular risk [43].
A number of therapeutic agents that preferentially lower
postmeal plasma glucose are currently available. These
therapies include 
 
α
 
-glucosidase inhibitors, glinides (rapid-
acting insulin secretagogues), rapid-acting insulin, biphasic
(premixed) insulins and human regular insulin. In addition,
newer classes of therapies have emerged that are also associated
with a reduction in PMG excursions and improvement in
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HbA
 
1c
 
. These agents include amylin analogues, glucagon-like
peptide-1 (GLP-1) derivatives and dipeptidyl peptidase-4
(DPP-4) inhibitors [44,45] (Table 1).
 
Recommendation
 
• A variety of both non-pharmacologic and pharmacologic
therapies should be considered to target postmeal plasma glucose.
 
Question 4: What are the targets for postmeal glycaemic 
control and how should they be assessed?
 
A 2-h postmeal goal of < 7.8 mmol/l (< 140 mg/dl) is recom-
mended, in line with targets published in guidelines from other
associations [8,39,46]. Such guidelines define normal glucose
tolerance (NGT) as post-challenge values of < 7.8 mmol/l 2 h
after ingestion of a 75-g glucose load [1,37], corresponding to
postmeal values of healthy individuals after meals [47]. The
2-h time frame for testing is also in agreement with published
guidelines and in addition reflects the 2- to 3-h return of
postmeal hyperglycaemia to basal levels in individuals with
normal glucose tolerance [39,46].
The guideline encourages performing glucose monitoring as
frequently as needed in order to guide therapy to achieve PMG
targets. In particular, the guideline suggests considering
self-monitoring of blood glucose (SMBG), as it is the only way
to directly assess PMG. However, some degree of controversy
surrounds SMBG use, particularly with respect to the frequency
of monitoring in non-insulin requiring diabetes [48]. Never-
theless, most professional diabetes organizations continue to
advocate its use [37,39,46], generally recommending that
self-monitoring is performed at least three times daily in
individuals treated with insulin and according to treatment
regimen and level of glycaemic control in non-insulin dependent
diabetes [37,38]. What is more, the use of structured SMBG
appears to result in a significant reduction in HbA
 
1c
 
, even in
individuals with non-insulin requiring diabetes [49]. These
findings support the implementation of SMBG as part of a
structured programme that may involve the training of
clinicians and patients to accurately interpret results and
adjust therapy accordingly in a timely manner.
 
Glycaemic goals for clinical management of diabetes
 
• HbA
 
1c
 
 < 6.5%
• Premeal (fasting) < 5.5 mmol/l (< 100 mg/dl)
• Two hours postmeal < 7.8 mmol/l (< 140 mg/dl)
Note: Lower glucose parameters to as near normal as safely
possible. Glycaemic targets should be individualized. These
goals are not appropriate for children and pregnant women.
 
Recommendations
 
• Two-hour postmeal plasma glucose should not exceed
7.8 mmol/l (140 mg/dl) as long as hypoglycaemia is avoided.
• Self-monitoring of blood glucose should be considered
because it is currently the most practical method for monitoring
postmeal glycaemia.
• Efficacy of treatment regimens should be monitored as
frequently as needed to guide therapy towards achieving
postmeal plasma glucose target.
 
Relevance of guideline and implications
 
The importance of managing PMG to improve overall glycaemic
control in diabetes is now fairly widely recognized in
guidelines from professional associations [2,37–39,46]. As the
research base continues to expand, the answers to other
relevant questions are eagerly anticipated, such as whether
there is a causal association between PMG and macrovascular
complications and the role of SMBG in individuals who are
not on insulin therapy. Until that time, logic and clinical
judgment preside when interpreting the evidence presented in
the guideline and deciding on an optimal management plan.
Management strategies should depend on a practical evaluation
of how best to integrate the recommendations into modern
practice, with consideration to locally available therapies and
resources.
 
Conclusions
 
Postmeal hyperglycaemia occurs early in the development of
diabetes, progressively worsens with deteriorating HbA
 
1c
 
 and
is often inadequately controlled. In addition, elevations in
Table 1 Therapeutic agents that preferentially lower postmeal plasma glucose and their mechanisms of action
Therapeutic class Physiological mechanism of action
Alpha-glucosidase inhibitors Delays carbohydrate absorption from the gastrointestinal tract
Amylin analogues Acts as a replacement for naturally occurring amylin, a hormone secreted by pancreatic B-cells along with 
insulin, that decreases glucagon release, slows gastric emptying and decreases food intake
DPP-4 inhibitors Inhibits DPP-4 enzyme that degrades GLP-1
Glinides Stimulates a rapid but short-lived release of insulin
GLP-1 derivatives Acts as a replacement for GLP-1, an incretin hormone secreted by the gut that stimulates insulin secretion, 
reduces glucagon secretion and delays gastric emptying rate
Rapid-acting insulins Developed to mimic physiological insulin response to meals with rapid onset and peak activity and short 
duration of action
DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1.
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PMG are strongly associated with a number of serious com-
plications of diabetes, both through a direct contribution to
HbA
 
1c
 
 as well as an independent association with various
diabetes-related complications. Based on evidence to date, the
guideline recommends implementing a comprehensive
management programme that targets both postmeal and
fasting glucose, which should be initiated simultaneously at
any HbA
 
1c
 
 level to improve outcome in diabetes. A variety of
both non-pharmacological and pharmacological therapies
should be considered to target postmeal plasma glucose.
Monitoring should occur as frequently as needed to guide
therapy and SMBG should be considered. Subject to available
therapies and resources, a 2-h postmeal plasma glucose target
of < 7.8 mmol/l (140 mg/dl) is considered both reasonable and
achievable.
 
Comment
 
Since publication of the guideline, results from an interventional
study of 644 outpatients with Type 2 diabetes demonstrated
that the glucose spike (i.e. the difference between premeal
glucose value and peak value of glycaemia during three different
meals) was the most important predictor of CIMT progression
compared with all examined glycaemic parameters, with peak
value of glycaemia occurring 1.5 h after the start of the meal [50].
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